Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis

Journal of Applied Physiology

Volumn 110, Issue 3, 2011, Pages 638-645

  Blanco, Isabel ^a   Ribas, Jesús ^b   Xaubet, Antoni ^a,c   Gómez, Federico P ^a,c   Roca, Josep ^a,c   Rodriguez Roisin, Robert ^a,c   Barberà, Joan A ^a,c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Gas exchange; Pulmonary circulation; Pulmonary hemodynamics; Vasodilator agents; Ventilation perfusion relationships

Indexed keywords

NITRIC OXIDE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; DRUG EFFECT; EXERCISE; EXERCISE TEST; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG GAS EXCHANGE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY ARTERY; VASCULAR RESISTANCE;

ADMINISTRATION, INHALATION; ADULT; AGED; EXERCISE TEST; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; NITRIC OXIDE; PHYSICAL EXERTION; PULMONARY ARTERY; PULMONARY GAS EXCHANGE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 79954593252     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01104.2010     Document Type: Article

References (40)

1. American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165: 277-304, 2002.
2. Agustí AG, Barberà JA. Contribution of multiple inert gas elimination technique to pulmonary medicine. 2. Chronic pulmonary diseases: Chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Thorax 49: 924-932, 1994.
3. Agusti AG, Barberà JA, Roca J, Wagner PD, Guitart R, Rodriguez- Roisin R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 97: 268-275, 1990. (Pubitemid 20050657)
4. Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 143: 219-225, 1991.
5. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez- Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 347: 436-440, 1996. (Pubitemid 26054069)
6. Blanco I, Gimeno E, Munoz PA, Pizarro S, Rodriguez-Roisin R, Roca J, Barbera JA. Hemodynamic and gas exchange effects of sildenafil in patients with COPD and pulmonary hypertension. Am J Respir Crit Care Med 181: 270-278, 2010.
7. Cardus J, Burgos F, Diaz O, Roca J, Barberà JA, Marrades RM, Rodriguez-Roisin R, Wagner PD. Increase in pulmonary ventilationperfusion inequality with age in healthy individuals. Am J Respir Crit Care Med 156: 648-653, 1997. (Pubitemid 27352008)
8. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131: 897-899, 2007. (Pubitemid 46446887)
9. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: A review. Sarcoidosis Vasc Diffuse Lung Dis 26: 7-19, 2009.
10. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T. Heterogeneous increase in CD34- positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169: 1203-1208, 2004. (Pubitemid 38680397)
11. Gale GE, Torre-Bueno JR, Moon RE, Saltzman HA, Wagner PD. Ventilation-perfusion inequality in normal humans during exercise at sea level and simulated altitude. J Appl Physiol 58: 978-988, 1985.
12. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet 360: 895-900, 2002. (Pubitemid 35283832)
13. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341: 1550-1554, 1993. (Pubitemid 23170459)
14. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221, 1995.
15. Gunther A, Enke B, Markart P, Hammerl P, Morr H, Behr J, Stahler G, Seeger W, Grimminger F, Leconte I, Roux S, Ghofrani HA. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: An open label study. Eur Respir J 29: 713-719, 2007. (Pubitemid 46554621)
16. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 109: 1566-1576, 1996. (Pubitemid 26193386)
17. Hlastala MP. Multiple inert gas elimination technique. J Appl Physiol 56: 1-7, 1984. (Pubitemid 14144302)
18. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
19. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620-628, 2010.
20. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gomez-Marin O. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 188: 115-123, 2010.
21. Katayama Y, Higenbottam TW, az de Atauri MJ, Cremona G, Akamine S, Barberà JA, Rodriguez-Roisin R. Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension. Thorax 52: 120-124, 1997. (Pubitemid 27086737)
22. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177: 75-81, 2008.
23. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review. Eur Respir J 34: 888-894, 2009.
24. Lynch JP, Mhyre JG, Dantzker DR. Influence of cardiac output on intrapulmonary shunt. J Appl Physiol 46: 315-321, 1979. (Pubitemid 9158778)
25. Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 44: 372-376, 2006.
26. Maruyama K, Kobayasi H, Taguchi O, Chikusa H, Muneyuki M. Higher doses of inhaled nitric oxide might be less effective in improving oxygenation in a patient with interstitial pulmonary fibrosis. Anesth Analg 81: 210-211, 1995.
27. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld- Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160: 600-607, 1999. (Pubitemid 29380679)
28. Roger N, Barberà JA, Farre R, Cobos A, Roca J, Rodriguez-Roisin R. Effect of nitric oxide inhalation on respiratory system resistance in chronic obstructive pulmonary disease. Eur Respir J 9: 190-195, 1996. (Pubitemid 26068610)
29. Ross B, Orleans-Juste P, Giaid A. Potential role of endothelin-1 in pulmonary fibrosis: From the bench to the clinic. Am J Respir Cell Mol Biol 42: 16-20, 2010.
30. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 82: 342-350, 2007. (Pubitemid 46348935)
31. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30: 715-721, 2007. (Pubitemid 351194832)
32. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 59: 581-585, 2004. (Pubitemid 38901516)
33. Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med 34: 994-1001, 2008.
34. 2 concentration. J Appl Physiol 71: 2191-2197, 1991.
35. Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 44: 118-127, 1983. (Pubitemid 13189310)
36. Wilson JR, Kapoor SC. Contribution of prostaglandins to exerciseinduced vasodilation in humans. Am J Physiol Heart Circ Physiol 265: H171-H175, 1993. (Pubitemid 23224706)
37. Xaubet A, Ancochea J, Blanquer R, Montero C, Morell F, Rodriguez BE, Sueiro A, Villena V. [Diagnosis and treatment of diffuse interstitial lung diseases]. Arch Bronconeumol 39: 580-600, 2003. (Pubitemid 38004945)
38. Yamakami T, Taguchi O, Gabazza EC, Yoshida M, Kobayashi T, Kobayashi H, Yasui H, Ibata H, Adachi Y. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. Eur Respir J 10: 2055-2060, 1997. (Pubitemid 27406441)
39. Yung GL, Kriett JM, Jamieson SW, Johnson FW, Newhart J, Kinninger K, Channick RN. Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: A bridge to lung transplantation. J Heart Lung Transplant 20: 1224-1227, 2001. (Pubitemid 33035085)
40. 2 max in young healthy men. Physiol Res 58: 229-238, 2009.